As DNA-encoded library (DEL) technology becomes increasingly embraced as a frontline screening tool, more and more companies seek to develop a DEL capability. They want the flexibility and scalability that comes from internally operating the platform. One perceived impediment, however, is the time and cost of creating a DEL collection of sufficient scope, quality and diversity to drive successful hit generation. The upfront costs of establishing the capability can be substantial: